Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
Phase of Trial: Phase IV
Latest Information Update: 19 Nov 2015
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 19 Nov 2015 New trial record